Increased EAT volume after anthracycline chemotherapy is associated with a low risk of cardiotoxicity in breast cancer
- Authors
- Kwon, Seong Soon; Nam, Bo Da; Lee, Min-Young; 이민혁; Lee, Jihyoun; Park, Byoung-Won; Bang, Duk Won; Kwon, Soon Hyo
- Issue Date
- Nov-2022
- Publisher
- Kluwer Academic Publishers
- Keywords
- Anthracycline; Breast cancer; Epicardial adipose tissue; Subclinical cardiotoxicity
- Citation
- Breast Cancer Research and Treatment, v.196, no.1, pp 111 - 119
- Pages
- 9
- Journal Title
- Breast Cancer Research and Treatment
- Volume
- 196
- Number
- 1
- Start Page
- 111
- End Page
- 119
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21637
- DOI
- 10.1007/s10549-022-06696-z
- ISSN
- 0167-6806
1573-7217
- Abstract
- Purpose Chemotherapy-induced cardiotoxicity is a critical issue for patients with breast cancer. Change of epicardial adipose tissue (EAT) is associated with cardiac dysfunction. The objective of this study was to investigate the relationship between EAT and chemotherapy-induced cardiotoxicity. Methods This retrospective study analyzed EAT on chest computed tomography (CT) of patients with early breast cancer using automatic, quantitative measurement software between November 2015 and January 2020. Changes in EAT before and after initiation of chemotherapy were compared according to the type of anticancer drug. Subclinical cardiotoxicity was defined as worsening >= 10% in left ventricular ejection fraction to an absolute value > 50% with a lower limit of normal measured with standard echocardiography. Results Among 234 patients with breast cancer, 85 were treated with adjuvant anthracycline-based (AC) and 149 were treated with non-anthracycline-based (non-AC) chemotherapy. There was a significant increase in EAT volume index (mL/kg/m(2)) at the end of chemotherapy compared to that at the baseline in the AC group (3.33 +/- 1.53 vs. 2.90 +/- 1.52, p < 0.001), but not in the non-AC group. During the follow-up period, subclinical cardiotoxicity developed in 20/234 (8.6%) patients in the total population [13/85 (15.3%) in the AC group and 7/149 (4.8%) in the non-AC group]. In the multivariable analysis, EAT volume index increment after chemotherapy was associated with a lower risk of subclinical cardiotoxicity in the AC group (Odds ratio: 0.364, 95% CI 0.136-0.971, p = 0.044). Conclusions Measurement of EAT during anthracycline-based chemotherapy might help identify subgroups who are vulnerable to chemotherapy-induced cardiotoxicity. Early detection of EAT volume change could enable tailored chemotherapy with cardiotoxicity prevention strategies.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of General Surgery > 1. Journal Articles
- College of Medicine > Department of Radiology > 1. Journal Articles
- College of Medicine > Department of Internal Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/21637)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.